Sort   by:  
 Page size 
UnknownPhase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
Not available
S-EPMC4021043 | biostudies-literature
TranscriptomicsSox2 promotes malignancy in glioblastoma by regulating plasticity and astrocytic differentiation
Making use of a previously described isogenic cancer stem cells and serum differentiated cultures we show that Sox2 controls developmental stated specific programs in glioblastoma. Glioblastoma cells were cultured as control and with SOX2 knockdown to identify the scope of SOX2 interactions. The SOX...
ORGANISM(S): Homo sapiens 
2014-07-22 | E-GEOD-51441 | biostudies-arrayexpress
Genomicsena-DATASET-GBM-18-12-2014-13:16:58:171-201 - samples
Description not provided
EGAD00001001110 | EGA
GenomicsGBM_Triplet_GWSNP6_Case - samples
Case samples using SNP 6.0 Array
EGAD00010000656 | EGA
Genomicsena-DATASET-GBM-18-12-2014-13:23:12:439-204 - samples
Description not provided
EGAD00001001112 | EGA
Genomicsena-DATASET-GBM-18-12-2014-13:35:47:554-206 - samples
Description not provided
EGAD00001001113 | EGA
Genomicsena-DATASET-GBM-18-12-2014-13:21:42:962-203 - samples
Description not provided
EGAD00001001111 | EGA
Genomicsena-DATASET-GBM-18-12-2014-13:14:47:525-200 - samples
Description not provided
EGAD00001001109 | EGA
GenomicsGBM_Triplet_GWSNP6_Control - samples
Control samples using SNP 6.0 Arrays
EGAD00010000654 | EGA
GenomicsSpatial and temporal genomic evolution in glioblastoma
Tumor heterogeneity is a challenging barrier to successful targeted therapy in glioblastoma. Identifying the mechanisms that drive cancer cells as they genetically evolve and adapt in response to treatment is a vital goal of modern cancer research. Analysis of sequencing data provides a method for u...
EGAS00001001033 | EGA
Sort   by:  
 Page size